Showing 2831-2840 of 5621 results for "".
- Carl Zeiss Meditec to Acquire IanTECH, Maker of the miLOOP Device for Cataract Surgeryhttps://modernod.com/news/carl-zeiss-meditec-to-acquire-iantech-maker-of-the-miloop-device-for-cataract-surgery/2479758/Carl Zeiss Meditec announced it has entered into an agreement to acquire IanTECH, the manufacturer of the miLOOP device for cataract surgery. miLOOP is a microinterventional device designed to deliver energy-free endocapsular lens fragmentation independent of phaco energy. Terms of the d
- Alcon to Develop SMART Suite Digital Health Platform for Cataract Surgeryhttps://modernod.com/news/alcon-to-develop-smart-suite-digital-health-platform-for-cataract-surgery/2479762/Alcon announced plans to develop the SMART Suite by Alcon, a digital platform that is designed to streamline, simplify, and improve cataract surgery for surgeons and patients. The SMART Suite by Alcon will connect multiple diagnostic and surgical devices through a digital, open cloud-based
- LEH Pharma Appoints Syneos Health as Global Clinical Development and Commercialization Solutions Providerhttps://modernod.com/news/leh-pharma-appoints-syneos-health-as-global-clinical-development-and-commercialization-solutions-provider/2479769/LEH Pharma, a provider of ocular implants for macular disorders, announced the selection of Syneos Health, a fully integrated biopharmaceutical solutions organization, as its global clinical development and commercialization provider. The primary aim of the strategic relationship is to acc
- Hoya Surgical Optics to Acquire Ophthalmic Medical Device Companies Mid Labs, Fritz Ruckhttps://modernod.com/news/hoya-surgical-optics-to-acquire-ophthalmic-medical-device-companies-mid-labs-fritz-ruck/2479775/Hoya Surgical Optics announced that it has entered into a definitive agreement to acquire two medical device companies: US-based Mid Labs and Germany-based Fritz Ruck. Mid Labs is a California-based company focused on the research, innovation, development, engineering, and manufacturin
- Altris.AI Partners With Huvitz for Development of AI-Based Retinal Detectionhttps://modernod.com/news/altris-ai-the-new-era-of-retinal-diagnosis-is-coming/2479785/Artificial intelligence company Altris.Al announced it has signed an agreement with South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co. aimed at the development of customized deep learning solutions for retinal diseases detection. Terms of the deal were not disclo
- In-Clinic Hurdles for AI-Based Diabetic Retinopathy Detectionhttps://modernod.com/news/in-clinic-hurdles-for-ai-based-diabetic-retinopathy-detection/2479810/Researchers found mixed results when they tested an artificial intelligence (AI)‒based system for detecting diabetic retinopathy (DR) in a real-world primary care setting in Midland, Australia, according to a Medscape report. In th
- New Display Design Could Make Lightweight, Compact Smart Glasses a Realityhttps://modernod.com/news/new-display-design-could-make-lightweight-compact-smart-glasses-a-reality/2479811/Researchers have developed a fundamentally new approach to a see-through display for augmented reality, or smart glasses. By projecting images from the glass directly onto the eye, the new design could one day make it possible for a user to see information such as directions or restaurant ratings
- Eyevance Acquires Global Rights to Persistent Corneal Epithelial Defect Treatment Nexagonhttps://modernod.com/news/eyevance-acquires-global-rights-to-persistent-corneal-epithelial-defect-treatment-nexagon/2479822/Eyevance Pharmaceuticals announced a worldwide licensing agreement with OcuNexus Therapeutics for Nexagon, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care. Terms of the deal were not disc
- AAO: New Study Confirms Mediterranean Diet Prevents AMD Developmenthttps://modernod.com/news/aao-new-study-confirms-mediterranean-diet-prevents-a-leading-cause-of-blindness/2479827/Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD). A large
- PeptiDream Announces Drug Discovery and Development Agreement with Santen Pharmaceuticalhttps://modernod.com/news/peptidream-announces-drug-discovery-and-development-agreement-with-santen-pharmaceutical/2479839/PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company, announced that it has entered into a broad-based multi-target discovery and development agreement with Osaka-based Santen Pharmaceuticals. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform